Li XM, Luo BH, Wang ZY, Yuan J, Han GH. Baveno VII - Renewing consensus in portal hypertension: personalized care for portal hypertension. Zhonghua Gan Zang Bing Za Zhi. 2022;30:21–29.

CAS  PubMed  Google Scholar 

Kaplan DE, Ripoll C, Thiele M et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79:1180–1211.

PubMed  Google Scholar 

Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65:310–335.

PubMed  Google Scholar 

Hou MC, Lin HC, Kuo BI et al. Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: a prospective randomized trial. Hepatology. 1995;21:1517–1522.

CAS  PubMed  Google Scholar 

de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–752.

PubMed  Google Scholar 

Bañares R, Moitinho E, Piqueras B et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology. 1999;30:79–83.

PubMed  Google Scholar 

Aguilar-Olivos N, Motola-Kuba M, Candia R et al. Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: systematic review and meta-analysis. Ann Hepatol. 2014;13:420–428.

CAS  PubMed  Google Scholar 

Reiberger T, Ulbrich G, Ferlitsch A et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62:1634–1641.

CAS  PubMed  Google Scholar 

Villanueva C, Albillos A, Genescà J et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393:1597–1608.

CAS  PubMed  Google Scholar 

Kalambokis GN, Christaki M, Tsiakas I et al. Conversion of propranolol to carvedilol improves renal perfusion and outcome in patients with cirrhosis and ascites. J Clin Gastroenterol. 2021;55:721–729.

CAS  PubMed  Google Scholar 

Sharma S, Agarwal S, Gunjan D et al. Long-term outcomes with carvedilol versus propranolol in patients with index variceal bleed: 6-year follow-up study. J Clin Exp Hepatol 2021;11:343–353.

CAS  PubMed  Google Scholar 

Gupta V, Rawat R, Saraya A. Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT. Hepatol Int 2017;11:181–187.

PubMed  Google Scholar 

McDowell HR, Chuah CS, Tripathi D, Stanley AJ, Forrest EH, Hayes PC. Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study. Aliment Pharmacol Ther. 2021;53:531–539.

CAS  PubMed  Google Scholar 

Jachs M, Hartl L, Simbrunner B et al. Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis. Clin Gastroenterol Hepatol. 2023;21:2318-2326.e7.

CAS  PubMed  Google Scholar 

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–1457.

Google Scholar 

Corrigendum to "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis" [J Hepatol 69 (2018) 406–460]. J Hepatol. 2018. 69(5): p. 1207.

Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652–659.

PubMed  Google Scholar 

Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362:823–832.

CAS  PubMed  Google Scholar 

Tripathi D, Stanley AJ, Hayes PC et al. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;64:1680–1704.

PubMed  Google Scholar 

Angeli P, Bernardi M et al. Villanueva: EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.

Google Scholar 

Kim SG, Kim TY, Sohn JH et al. A randomized, multi-center, open-label study to evaluate the efficacy of carvedilol vs. propranolol to reduce portal pressure in patients with liver cirrhosis. Am J Gastroenterol. 2016;111:1582–1590.

CAS  PubMed  Google Scholar 

Albillos A, Krag A. Beta-blockers in the era of precision medicine in patients with cirrhosis. J Hepatol. 2023;78:866–872.

CAS  PubMed  Google Scholar 

Wang B, Zhou J, Wu X et al. Carvedilol plus NUC for patients With HBV-compensated cirrhosis under virological suppression: a randomized open-label trial. Am J Gastroenterol. 2024;119:700–711.

CAS  PubMed  Google Scholar 

Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJ, de Martel C. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 2022;7:724–735.

CAS  PubMed  PubMed Central  Google Scholar 

EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010. 53: p. 397–417.

Singh V, De A, Mehtani R et al. Asia-Pacific association for study of liver guidelines on management of ascites in liver disease. Hepatol Int. 2023;17:792–826.

PubMed  Google Scholar 

Bañares R, Moitinho E, Matilla A et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology. 2002;36:1367–1373.

PubMed  Google Scholar 

Ramanathan S, Khandelwal N, Kalra N et al. Correlation of HVPG level with ctp score, MELD score, ascites, size of varices, and etiology in cirrhotic patients. Saudi J Gastroenterol. 2016;22:109–115.

PubMed  PubMed Central  Google Scholar 

Tripathi D, Therapondos G, Lui HF, Stanley AJ, Hayes PC. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther. 2002;16:373–380.

CAS  PubMed  Google Scholar 

Stanley AJ, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol. 1999;30:479–484.

CAS  PubMed  Google Scholar 

Cheung KS, Mok CH, Lam LK, Mao XH, Mak LY, Seto WK, Yuen MF. Carvedilol versus other nonselective beta blockers for variceal bleeding prophylaxis and death: a network meta-analysis. J Clin Transl Hepatol. 2023;11:1143–1149.

PubMed  PubMed Central  Google Scholar 

Cho Y, Bukong TN, Tornai D, Babuta M, Vlachos IS, Kanata E, Catalano D, Szabo G. Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcohol-associated hepatitis. J Hepatol. 2023;78:28–44.

CAS  PubMed  Google Scholar 

Muratori L, Lohse AW, Lenzi M. Diagnosis and management of autoimmune hepatitis. Bmj. 2023;380:e070201.

CAS  PubMed  Google Scholar 

Khan RS, Lalor PF, Thursz M, Newsome PN. The role of neutrophils in alcohol-related hepatitis. J Hepatol. 2023;79:1037–1048.

CAS  PubMed  Google Scholar